Search
Roivant Sciences Ltd
ROIVAdd to Watchlist
33.705USD
+1.495+4.64%
Market hours （ET）Quotes delayed by 15 min
23.92BMarket Cap
LossP/E TTM
More Details of Roivant Sciences Ltd Company
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltd Info
Ticker SymbolROIV
Company nameRoivant Sciences Ltd
IPO dateDec 03, 2020
CEOVenker (Eric)
Number of employees750
Security typeOrdinary Share
Fiscal year-endDec 03
Address7Th Floor, 50 Broadway
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeSW1H 0DB
Phone4412955950
Websitehttp://roivant.com/
Ticker SymbolROIV
IPO dateDec 03, 2020
CEOVenker (Eric)
Company Executives of Roivant Sciences Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.58M
-1.18%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.75%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.46M
-2.36%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
113.36K
+13.79%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
101.64K
+0.79%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
93.00K
+0.40%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
--
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
76.72K
-24.71%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
68.00
-60575.00%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
--
-100.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.58M
-1.18%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.75%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.46M
-2.36%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
113.36K
+13.79%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
101.64K
+0.79%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
93.00K
+0.40%
FAQs
Who are the top five shareholders of Roivant Sciences Ltd?
The top five shareholders of Roivant Sciences Ltd are: Dr. Frank M. Torti, M.D.
How many institutions hold shares of Roivant Sciences Ltd (ROIV)?
As of 2026Q1, 781 institutions hold shares of Roivant Sciences Ltd, with a combined market value of approximately 565.52M, accounting for 79.01% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -23023750.00.
